← All Akoustis Technologies, INC filings

Akoustis Technologies, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AKTS
Akoustis Technologies, INC
10-K: Aktis Oncology posts 2025 loss, extends cash runway
Clinical-stage radiopharma Aktis Oncology reported a $63.7M 2025 net loss, strengthened liquidity with a $335.3M January 2026 IPO and Lilly collaboration, and guided cash runway into 2029 as it advances Nectin-4 and B7-H3 programs.
NASDAQ
AKTS
Akoustis Technologies, INC
10-K/A: Akoustis Technologies Files Amended 10-K to Include Cybersecurity Disclosures
Akoustis Technologies has filed an amendment to its annual report to include cybersecurity risk disclosures and updated certifications from its CEO and CFO.
NASDAQ
AKTS
Akoustis Technologies, INC
10-K: Akoustis Technologies Faces Going Concern Doubts Amidst Legal Setback and Financial Strain
Akoustis Technologies reports a challenging fiscal year marked by a significant legal loss, substantial operating losses, and doubts about its ability to continue as a going concern.